CMS Defends Oral ESRD Drug Inclusion In Proposed Bundling Rule
In anticipation of objections to its proposal to include oral end-stage renal disease drugs currently covered under Medicare Part D in bundled payments for ESRD services, CMS offered an extensive justification for the action